Case-control study reveals lower Helicobacter pylori seroprevalence in rheumatoid arthritis patients with lung disease, suggesting a potential protective role against pulmonary complications.
Background: Rheumatoid arthritis (RA) is complicated with interstitial lung disease (ILD). Gastroesophageal reflux disease is prevented by Helicobacter pylori infection and is a predisposing factor for idiopathic pulmonary fibrosis. However, the prevalence of H. pylori infection in RA patients with ILD has not been sufficiently investigated. Objective: In this study, we analyzed anti- H. pylori antibodies in RA patients with ILD. Design: Case-control observational study Methods: Anti- H. pylori antibodies were analyzed in the sera of RA patients using a commercially available enzyme-linked immunosorbent assay kit. Results: The positivity of anti- H. pylori antibodies in RA with ILD ( n = 30 [18.0%], P = .0227), usual interstitial pneumonia ( n = 10 [14.3%], P = .0212), and airway disease ( n = 30 [18.0%], P = .0227) was significantly lower than that of RA without chronic lung disease ( n = 78 [27.5%]). The positivity of anti- H. pylori antibodies was also lower in RA with chronic lung disease ( n = 68 [18.2%], P = .0059). Multiple logistic regression analyses showed that the presence of anti- H. pylori antibodies was independently and protectively associated with chronic lung disease in RA. Conclusion: The seroprevalence of H. pylori was lower in RA with ILD. H. pylori infection prevented ILD in patients with RA by protecting them from gastroesophageal reflux disease.
No takes yet. Share an insight, caveat, or question.
Oka et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: